What does the next wave of PGx advancement involve shifting away from in terms of testing methodology?
Answer
Targeted, single-gene tests.
The progression of pharmacogenomics testing is marked by a significant evolutionary leap beyond the current standard. Presently, testing often targets specific, well-established interactions involving a single gene or a very limited set of markers relevant to one drug. The next major advancement dictates a move toward broader genetic evaluations capable of informing treatment decisions across multiple drug classes simultaneously. This involves looking past isolated genetic markers to incorporate more comprehensive genomic data capture methods, suggesting a move toward larger panels or re-analysis of whole-genome sequencing data.
Related Questions
What is the fundamental aim of personalized medicine enabled by Pharmacogenomics (PGx)?What does the next wave of PGx advancement involve shifting away from in terms of testing methodology?What feature do Polygenic Risk Scores (PRS) aggregate to predict complex traits like drug response?How does the future vision of PGx testing redefine the timing of its application compared to current practices?What process is deemed crucial for embedding PGx insights directly into the electronic health record (EHR) and clinical workflow?What sophisticated capability should future Clinical Decision Support Systems (CDSS) possess regarding prescription writing?How is Artificial Intelligence (AI) and Machine Learning (ML) expected to improve drug response predictions beyond current rule-based systems?What two primary barriers are identified as crucial factors hindering the widespread scaling and equitable access of PGx testing?What specialized task will pharmacists perform by translating raw genotype data in the PGx pathway?What regulatory clarity is expected in the future regarding drug labels and PGx guidance from bodies like the FDA?